Sept 9 (Reuters) – Regeneron Prescribed drugs mentioned on Wednesday it expects to report biomarker knowledge for its COVID-19 antibody cocktail by the tip of this month.
The drugmaker final month struck a partnership with Roche AG to make and provide the COVID-19 antibody cocktail, which is being examined on a number of tons of of sufferers after it prevented and handled the respiratory illness in animals.
Regeneron has already signed a $450 million deal for the cocktail with the U.S. authorities, underneath the Trump administration’s “Operation Warp Pace” program that’s aimed on the quicker distribution of vaccines and coverings to battle the brand new coronavirus when trials are profitable.
The corporate mentioned on Wednesday it was shifting manufacturing of a few of its merchandise to Eire to extend the manufacturing capability of the cocktail and would possibly search for different provide companions if there’s lots of demand.
Regeneron’s cocktail, REGN-COV2, comprises an antibody made by the corporate and one other remoted from recovered COVID-19 sufferers. Rivals Eli Lilly and AbbVie are additionally pursuing antibody therapies for the respiratory sickness.
Shares of Regeneron have been up 1.4% at $569.68. (Reporting by Trisha Roy in Bengaluru; Modifying by Aditya Soni)